National and Kapodistrian University of Athens
Ιn vitro και in vivo μελέτη της βακτηριοκτόνου δράσεως των καρβαπενεμών έναντι εντεροβακτηριακών που παράγουν μεταλλοένζυμα της ομάδας VIM
Abstract
dc:descriptionOBJECTIVES: Evaluation of the antimicrobial activity of carbapenems against VIMmetallo-β-lactamase-producing Enterobactericeae, including Klebsiella pneumoniae isolates,using in vitro ( MIC, killing curves) and in vivo methodologies (murine thigh model).METHODS: Seven VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae isolatesexhibiting different levels of susceptibility to carbapenems were studied. Isolates wererecovered from blood cultures of patients treated in five Athens hospitals during the period2003-2005. Species identification was performed using the API20E system (BioMerieux).Isolates were typed by pulsed field gel electrophoresis (PFGE). The presence of blaVIM-1 genewas confirmed by polymerase chain reaction (PCR) and nucleotide sequencing. Antibioticsusceptibility status of the isolates to selected antimicrobials was assessed by (a) the Kirby-Bauer method, (b) determination of minimum inhibitory concentrations (MIC) using E-testand (c) determination of MICs and minimum bactericidal concentrations (MBCs) using amicrodilution method. In vitro time-kill assays were performed with different inocula (104,106 and 108 cfu/ml) using carbapenems (imipenem, meropenem and ertapenem) as well asother antimicrobial agents (aztreonam and gentamicin). A β-lactam-susceptible Klebsiellapneumoniae strain lacking any acquired bla gene and expressing only the species specificblaSHV-1 was used as a control. For the experimental murine thigh infection, animals that hadbeen rendered neutropenic after treatment with cyclophosphamide were used. Mice were infected with three VIM-1 positive isolates with representative carbapenem MICs (lowintermediate and high). The wild-type VIM-negative isolate was also utilized for controlpurposes. The carbapenems (imipenem and meropenem) were applied in two dosingregimens, 30 and 60 mg/kg q2h given by intaperitoneal injections (a total dose of 360 and 720mg/kg) respectively.RESULTS: All isolates exhibited resistance phenotypes compatible with production of VIMmetallo-β-lactamase. They expressed either resistance or reduced susceptibility tocarbapenems according to the CLSI 2010 criteria. In time-kill assays there was an enhancedmicrobial killing especially during the first hours, for the lowest inoculum and the highestcarbapenem concentration. An inversely proportional correlation between the MIC of theisolate and the rate as well as the duration of killing in the presence of a carbapenem wasevident. Nevertheless, the reduction rate of colony forming units (cfu) (viable cells) wasminimum for the highest inoculum (108 cfu/ml) with the susceptible control isolate. Complete microbial killing within 24 hours was observed for the low inoculum (104 fu/ml) for allisolates and the intermediate inoculum (106 cfu/ml) for the susceptible control isolate and thehighest carbapenem concentrations. Α logarithmic reduction of the initial inoculum inverselyproportional to the MIC of the isolate was seen; however, bacterial regrowth was evident at24 hours. A strong inoculum effect was observed with both carbapenems. In the murine thighinfection model the antimicrobial efficacy of carbapenems was high against the VIM-negativecontrol isolate, intermediate against the VIM-positive isolate with the lower MIC and low onthe VIM-positive isolate with the higher carbapenem MICs. Both treatment regimensachieved drug plasma levels above the MIC (T > MIC) 33 - 45% with favourable bactericidalactivity for isolates with MIC ≤ 4 μg/ml. The therapeutic regimen with the higher carbapenemdosage displayed greater bactericidal activity for all isolates. Μeropenem exhibited in vivosuperior antibacterial activity than imipenem against isolate with the same MIC to the drug.CONCLUSION: Based on accumulated clinical experience, it has been proposed thatcarbapenems may be selectively used in serious hospital infections such as bacteremias,caused by carbapenemase-producing enterobacteria. Results of the present animalexperimental study provide further support to the hypothesis that the drugs of this class(preferentially meropenem) may have a place in the treatment of these life- threatening infections.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2013
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Panagiotakopoulou, Aggeliki
- Παναγιωτακοπούλου, Αγγελική
Subjects
dc:subject × 12Rights
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/40474